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Helicobacter pylori infection is the main cause of gastritis, gastroduodenal ulcer disease, and gastric cancer. After 30 years of
experience in H. pylori treatment, however, the ideal regimen to treat this infection has still to be found. Nowadays, apart from
having to know well ﬁrst-line eradication regimens, we must also be prepared to face treatment failures. In designing a treatment
strategy, we should not only focus on the results of primary therapy alone but also on the ﬁnal—overall—eradication rate. The
choice of a “rescue” treatment depends on which treatment is used initially. If a ﬁrst-line clarithromycin-based regimen was
used, a second-line metronidazole-based treatment (quadruple therapy) may be used afterwards, and then a levoﬂoxacin-based
combination would be a third-line “rescue” option. Alternatively, it has recently been suggested that levoﬂoxacin-based “rescue”
therapy constitutes an encouraging 2nd-line strategy, representing an alternative to quadruple therapy in patients with previous
PPI-clarithromycin-amoxicillin failure, with the advantage of eﬃcacy, simplicity and safety. In this case, quadruple regimen may
be reserved as a 3rd-line “rescue” option. Even after two consecutive failures, several studies have demonstrated that H. pylori
eradication can ﬁnally be achieved in almost all patients if several “rescue” therapies are consecutively given.
1.Introduction
Helicobacter pylori infection is the main known cause of
gastritis, gastroduodenal ulcer disease, and gastric cancer.
After 30 years of experience in H. pylori treatment, however,
the ideal regimen to treat this infection has still to be
found [1–3]. Consensus conferences have recommended
therapeutic regimens that achieve H. pylori cure rates higher
than 80% on an intention-to-treat basis [4–7]. However,
several large clinical trials and meta-analyses have shown
that the most commonly used ﬁrst-line therapies, including
proton pump inhibitors (PPIs) plus two antibiotics, may fail
in ≥20% of patients [8, 9], and in the clinical routine setting,
the treatment failure rate might be even higher [10, 11].
Moreover, during the last few years, the eﬃcacy of PPI-based
regimens seems to be decreasing, and several studies have
reported intention-to-treat eradication rates lower than 75%
and even lower than 50% [12–15]. Antibiotic resistance to
clarithromycinhasbeenidentiﬁedasoneofthemajorfactors
aﬀecting our ability to cure H. pylori infection, and the rate
of resistance to this antibiotic seems to be increasing in many
geographical areas [16–19].
Several “rescue” therapies have been recommended, but
they still fail to eradicate H. pylori in more than 20% of the
cases, and these patients constitute a therapeutic dilemma
[20–22]. Patients who are not cured with two consecutive
treatments including clarithromycin and metronidazole will
have at least single, and usually double, resistance [17, 23].
Furthermore, bismuth salts are not available worldwide any-
more; therefore, management of ﬁrst-line eradication fail-
ures is becoming challenging. Currently, a standard third-
line therapy is lacking, and European guidelines recommend
culture in these patients to select a third-line treatment
according to microbial sensitivity to antibiotics [5, 6]. How-
ever, cultures are often carried out only in research centers,
andtheuseofthisprocedureas“routinepractice”inpatients
who failed several treatments seems not to be feasible [20,
21, 24–26]. Therefore, the evaluation of drugs without cross-
resistance to nitroimidazole or macrolides as components
of retreatment combination therapies would be worthwhile
[27, 28].
All these issues are important at the present time, but
they will be even more relevant in the near future, as2 Gastroenterology Research and Practice
therapy for H. pylori infection is becoming more and more
frequently prescribed. Therefore, the evaluation of second or
third “rescue” regimens for these problematic cases seems to
be worthwhile [29]. In designing a treatment strategy, we
should not focus on the results of primary therapy alone;
an adequate strategy for treating this infection should use
several therapies which, if consecutively prescribed, come as
closetothe100% curerateaspossible [20,21,25,26,30,31].
The aim of the present paper will be to review the
experience dealing with “nonresponders” to H. pylori erad-
ication therapy, and speciﬁcally with H. pylori “rescue”
therapies after failure of the ﬁrst-line eradication regimen.
As,atpresent,thecurrentmostprescribedﬁrst-lineregimens
include a combination of PPI plus two antibiotics, the
present paper will focus on “rescue” regimen when these
triple combinations fail. Bibliographical searches were per-
formed in the PubMed (Internet) database including studies
available until October 2011, looking for the following words
(all ﬁelds): pylori AND (retreatment OR re-treatment OR
rescue OR failure OR salvage OR second-line).
2. Is It Necessary to Perform CultureAfter
Failureof the FirstEradicationTreatment?
Pretreatment antibiotic resistance is the most important
factor in nonresponse to initial treatment [32]. Thus, the
choice of a second-line treatment depends on which treat-
ment was used initially, as it would appear that retreatment
with the same regimen cannot be recommended [33]. If a
clarithromycin-based regimen was used, a metronidazole-
based treatment (or at least a clarithromycin-free regimen)
should be used afterwards, and vice versa [34]. This recom-
mendation is based on the observation that acquired bac-
terial resistance to metronidazole or clarithromycin results
primarily from the previous treatment failure [32], and
therefore “rescue” therapies should avoid these antibiotics
and use diﬀerent combinations.
An antimicrobial susceptibility test for H. pylori before
second-line treatment is sometimes performed, although
whether the test is truly necessary remains unknown. Some
authors have evaluated the eﬃcacy of susceptibility-guided
versus empiric retreatment for H. pylori after a treatment
failure. In the study by Yahav et al. [35], patients in whom
at least one treatment regimen for H. pylori eradication
had failed underwent gastric biopsy and culture and were
retreated according to the in vitro susceptibility results. Find-
ings were compared with those for control patients (where
culture was unavailable). Susceptibility-guided retreatment
was associated with better eradication rates (86%) than
empiric treatment (63%). However, several methodological
drawbacks exist in this study. Firstly, more than 50% of
the patients received ﬁrst-line eradication treatment with
bothclarithromycinandmetronidazole(insteadofincluding
clarithromycin and amoxicillin), which is not the generally
recommended combination; consequently, no logical empir-
ical treatment remained afterwards (levoﬂoxacin-based reg-
imens were not available at that time). In this respect, when
only the eradication rates in control (culture unavailable)
patients treated with a ﬁrst regimen of PPI-amoxicillin-clar-
ithromycin followed by a second empiric quadruple regimen
were considered (the generally recommended ﬁrst- and
second-line strategies), the success ﬁgures were not signif-
icantly diﬀerent from those reported in patients receiving
susceptibility-guided retreatment. Secondly, because this
study was nonrandomized, there might have been hetero-
geneity among the two groups with respect to the treatment
regimens prescribed by the treating physicians. Finally, this
study was limited by the lack of susceptibility data for
the controls, which restricted the ability to analyze the
reasons why empiric therapy did not work as well as the
susceptibility-guided protocol.
In a French multicenter study [36], patients, in whom
one previous H. pylori eradication therapy (mainly with PPI-
amoxicillin-clarithromycin) has failed, were randomized to
receive one of three empirical triple-therapy regimens or
a strategy based on antibiotic susceptibility. The empirical
regimens were PPI-amoxicillin-clarithromycin (for 7 or 14
days) or PPI-amoxicillin-metronidazole (for 14 days). In the
susceptibility-based strategy, patients with clarithromycin-
susceptible strains received PPI-amoxicillin-clarithromycin,
whilst the others received PPI-amoxicillin-metronidazole.
The eradication rates for empirical therapies were low,
while the cure rate was higher (74%) for the susceptibility-
based treatment. If the H. pylori strain was clarithromycin-
susceptible (which occurred in approximately 1/3 of the
cases), a high-success rate was obtained with the PPI-
clarithromycin-amoxicillin “rescue” regimen. The study,
however, was done in France, where bismuth is banned,
so that the use of quadruple therapy with a PPI, bismuth,
tetracycline, and metronidazole as recommended by the
updated Maastricht Consensus Report [6], was not tested.
In fact, as it will be reviewed later, several studies have
obtained relatively good results with this quadruple regi-
men empirically prescribed, with mean eradication rate of
77% (i.e., a similar ﬁgure than the 74% achieved for the
susceptibility-based treatment in the present study). Thus, in
this study, instead of not readministering any of the antibi-
otics against which H. pylori has probably become resis-
tant, the authors insist on prescribing again clarithromycin
(or metronidazole) for the second-line treatment. Further-
more, statistically signiﬁcant diﬀerences were not demon-
strated when comparing the eﬃcacy of the empirical
PPI-amoxicillin-metronidazole and the susceptibility-based
strategy, suggesting that the metronidazole-based com-
binationmaybeaneﬀectiveempiricalalternativeafterfailure
of a clarithromycin-based combination.
In the updated Maastricht Consensus Report [6], it
was recommended that culture and antimicrobial sensitivity
testing should be routinely performed only after two treat-
ment failures with diﬀerent antibiotics. According to this
statement, some studies have suggested that an antimicrobial
susceptibility test for H. pylori before administering second-
line treatment is not necessary. In this respect, in the study
by Avidan et al. [37], after failure of ﬁrst-line eradication
treatment, half of the patients were randomly assigned to
treatment with a diﬀerent PPI-based triple regimen regard-
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to treatment with PPI and two antibacterial agents chosen
according to a susceptibility test; the authors found that
the culture results did not inﬂuence the treatment protocol
employed. Similarly, in the study by Miwa et al [38], patients
with H. pylori infection for whom ﬁrst-line treatment with
a PPI-amoxicillin-clarithromycin regimen had failed were
randomlyassignedtotwogroups:thosehavingornothaving
the susceptibility test before retreatment. For those patients
in the susceptibility-test group, the authors used what they
considered the best regimen based on susceptibility testing;
while for those patients in the group with no susceptibility
testing, PPI-amoxicillin-metronidazole was prescribed. The
cure rates in the groups with and without susceptibility
testing were not diﬀerent.
3.Second-Line H. pylori “Rescue” Therapy
after Failureof One EradicationTreatment
3.1. “Rescue” Regimen after PPI-Clarithromycin-Amoxicillin
Failure
3.1.1. PPI, Amoxicillin, and Metronidazole. After failure of
a combination of PPI, amoxicillin, and clarithromycin, a
theoretically correct alternative would be the use, as second
option, of other PPI-based triple therapy including amox-
icillin (that does not induce resistance) and metronidazole
(an antibiotic not used in the ﬁrst trial), and several authors
have reported encouraging results with this strategy [38–
45]. However, in our experience, when this therapy has
been administered twice daily for one week, eradication rates
lower than 50% have been obtained [46]; the subsequently
use of higher (three times per day) antibiotic doses was
followed only by a mild increase in eradication rate (58%),
which was still unacceptable [46]. Nagahara et al. [47]
studiedagroupofpatientswho,afterfailureofﬁrst-linePPI-
clarithromycin-amoxicillintherapy,hadreceivedsecond-line
therapy with the same regimen (for 14 days) or had received
PPI-amoxicillin-metronidazole (for 10 days). The eradica-
tion rate for second-line therapy with the same regimen
(thus readministering clarithromycin) was of only 53%,
while it was of 81% with PPI-amoxicillin-metronidazole.
These observations underlie the idea that antibiotics, and
speciﬁcally clarithromycin, should not be readministered in
successive treatments.
3.1.2. Quadruple Therapy. Another alternative, the use of
a quadruple regimen (i.e., PPI, bismuth, tetracycline, and
metronidazole), has been generally used as the optimal
second-line therapy after PPI-clarithromycin-amoxicillin
failure and has been the recommended “rescue” regimen in
several guidelines [6, 48, 49]. Several studies have obtained
relatively good results with this quadruple regimen, the
results are summarized in Table 1 [46, 50–64]. Thus, the
weighted mean eradication rate with this “rescue” therapy,
calculated from the studies included in the table, is of 77%.
In this combination regimen, PPI should be prescribed in
the usual dose and twice a day, colloidal bismuth subci-
trate 120mg four times per day, tetracycline 500mg four
Table 1: Eradication rates with quadruple therapy (proton pump
inhibitor, bismuth, tetracycline, and a nitroimidazole) as “rescue”
therapy for proton pump inhibitor-clarithromycin-amoxicillin fail-
ure.
Author Number of
patients
Duration
(days)
Eradication
rate (%)
Baena et al. [50]3 1 1 4 9 0
Bilardi et al. [51]4 6 7 3 7
Elizalde et al. [52]3 1 78 7
Choung et al. [53]5 6 77 7
Choung et al. [53]9 9 1 4 8 8
Su et al. [54]8 7 7 8 4
Chung et al. [64]9 0 7 8 2
Chung et al. [64] 101 14 85
Gasbarrini et al. [55]9 7 8 8
Gisbert et al. [56]3 0 7 5 7
Gisbert et al. [46]9 7 7 8
Gomoll´ on et al. [57]2 1 7 9 5
Lee et al. [58]2 0 7 6 8
Lee et al. [59]6 3 7 7 5
Lee et al. [153] 112 7 64
Lee et al. [153] 115 10 83
Marko et al. [60]2 7 7 6 3
Michopoulos et al. [61]3 8 1 4 7 6
Navarro-Jarabo et al.
[62] 54 7 70
Nista et al. [63]7 0 7 6 3
Nista et al. [63]7 0 1 4 6 8
Orsi et al. [93]5 0 1 2 8 8
Perri et al. [154]4 5 1 0 6 7
Perri et al. [92]6 0 7 8 3
Sicilia et al. [155]2 1 1 0 8 3
Usta et al. [156]8 9 1 4 6 7
Uygun et al. [157] 100 14 82
Wong et al. [94]5 3 7 9 1
Wu et al. [158]4 7 7 7 7
Wu et al. [159]6 2 7 8 1
Eradication rates by intention-to-treat analysis when available. H. pylori
eradication rate (weighted mean) with quadruple therapy: 77%.
times per day, and metronidazole is probably best prescribed
at high doses (i.e., 500mg three times per day). Precisely, the
study with the lowest eﬃcacy [56] administered metronida-
zole at low doses (250mg four times per day). Although PPIs
are generally prescribed as the antisecretors in quadruple
therapy, some authors have shown, in a randomized study,
that omeprazole 20mg b.i.d. and ranitidine 300mg b.i.d.
were equally eﬀective as antisecretory agents combined in
a second-line quadruple eradication regimen after failure
with previous regimens without metronidazole (although
the power of the study to ﬁnd statistically signiﬁcant diﬀer-
ences was limited) [61]. Nevertheless, these regimens were
administered during 14 days; therefore, it remains to be4 Gastroenterology Research and Practice
demonstrated if the equivalence between both antisecre-
tors—PPIs and H2-blockers—is also observable with 7-day
or 10-day regimens.
The question may be suggested whether treatment with
PPI-clarithromycin-amoxicillin followed by “rescue” with
quadruple therapy if failure is preferable to the inverse
strategy. To analyze this interesting aspect, Gomoll´ on et al.
[65] randomized consecutive patients to one of two strate-
gies: (a) treatment during 7 days with quadruple ther-
apy, and if failure second-line treatment with omeprazole-
clarithromycin-amoxicillin during 7 days, (b) initial treat-
ment with omeprazole-clarithromycin-amoxicillin, and if
failuretreatmentwithquadrupletherapy.Directandindirect
costs were estimated, and a cost-eﬀectiveness analysis using a
decision-tree model was undertaken after real clinical data.
Eradication was obtained (intention-to-treat) in 73% with
the ﬁrst strategy, versus 92% with the second one. Further-
more, cost per case eradicated was lower in the second group
(320versus296Euros).However,inasimilarbutmorerecent
study, Marko et al. [60] assessed the usefulness and the cost-
eﬀectiveness of these two treatment strategies, performing
a decision analysis. The eﬀectiveness of “triple ﬁrst” and
“quadruple ﬁrst” strategies was similar, although the latter
seemed slightly more cost-eﬀective.
3.1.3. PPI, Amoxicillin, and Levoﬂoxacin. As previously men-
tioned, after failure of a combination of a PPI-based triple
regimen, the use of the quadruple therapy has been generally
recommended as the optimal second-line therapy based on
the relatively good results reported by several authors. How-
ever, this quadruple regimen requires the administration of
4 drugs with a complex scheme (bismuth and tetracycline
usually prescribed every 6 hours, and metronidazole every
8 hours) and is associated with a relatively high incidence
of adverse eﬀects [20]; however, this drawback may be over-
come, thanks to a novel single capsule containing bismuth,
metronidazole, and tetracycline that has recently become
available [66, 67]. Nevertheless, this quadruple regimen still
fails to eradicate H. pylori in approximately 20 to 30% of the
patients, and these cases constitute a therapeutic dilemma, as
patients who are not cured with two consecutive treatments
including clarithromycin and metronidazole will usually
have double resistance [20].
Levoﬂoxacin is a ﬂuoroquinolone antibacterial agent
with a broad spectrum of activity against Gram-positive and
Gram-negative bacteria and atypical respiratory pathogens
[68]. Recently, some studies have evaluated the eﬃcacy of
new ﬂuoroquinolones, such as levoﬂoxacin, that could prove
to be a valid alternative to standard antibiotics not only
as ﬁrst-line therapies but, more interesting, as second-line
regimens [21, 69–71]. In this respect, levoﬂoxacin-based
second-line therapies represent an encouraging strategy for
eradication failures, as some studies have demonstrated that
levoﬂoxacin has, in vitro, remarkable activity against H.
pylori [72], and that primary resistances to such antibiotic
in several countries are (still) relatively infrequent (when
compared with metronidazole or clarithromycin) [73–80].
Ar e c e n tin vitro study also showed a synergistic eﬀect
of quinolone antimicrobial agents and PPIs on strains of
H. pylori [81]. Furthermore, it has been shown in vitro that
levoﬂoxacin retains its activity when H. pylori strains are
resistant to clarithromycin and metronidazole [76, 82, 83].
These favorable results have been conﬁrmed in vivo, indicat-
ing that most of the patients with both metronidazole and
clarithromycin resistance are cured with the levoﬂoxacin-
based regimen [51, 75, 84, 85].
A combination of a PPI, amoxicillin and levoﬂoxacin, as
ﬁrst-line regimen, has been associated with favorable results,
with mean eradication rates of about 90% [76, 86–91].
Later, other authors studied this same regimen in patients
with one previous eradication failure, also reporting exciting
results, with H. pylori cures rates ranging from 60% to
94%% [51, 63, 82, 84, 91–104]. A recent systematic paper
showed a mean eradication rate with levoﬂoxacin-based
“rescue” regimens (combined with amoxicillin and a PPI
in most studies) of 80%, which represents a relatively high
ﬁgure when considering that this regimen was evaluated
as a “rescue” therapy [70]. This systematic paper found,
in agreement with recent randomized clinical trials [105],
higher H. pylori cure rates with 10-day than with 7-day
regimens, both in general (81% versus 73%) and also with
the levoﬂoxacin-amoxicillin-PPI combination in particular
(80% versus 68%), suggesting that the longer (10-day)
therapeutic scheme should be chosen.
Furthermore, three recent meta-analyses have suggested
that after H. pylori eradication failure, levoﬂoxacin-based
“rescue” regimen is more eﬀective than the generally rec-
ommended quadruple therapy [69, 70, 106]. In one of these
meta-analyses [70], higher H. pylori cure rates with the
levoﬂoxacin-based triple regimens than with the quadruple
combinations were found (81% versus 70%), but with
borderline statistical signiﬁcance (Figure 1). Nevertheless,
results were heterogeneous, mainly due to the discordant
results of the study by Perri et al. [92], who reported a
cure rate of only 63% with the levoﬂoxacin-regimen, the
lowest reported in the literature, a ﬁgure that contrasts with
the mean eradication rate of 80% calculated in a systematic
paper [70]. Nevertheless, when that single outlier study [92]
was excluded from the meta-analysis, the diﬀerence between
cure rates with both regimens reached statistical signiﬁcance
and heterogeneity markedly decreased. Furthermore, when
only high-quality studies were considered, the advantage
of the levoﬂoxacin regimen over the quadruple regimen
increased (88% versus 64%), also achieving statistical signif-
icance, and heterogeneity among studies almost disappeared
[70]. Nevertheless, the beneﬁt of the levoﬂoxacin-based
“rescue” regimen seems to be less clear in Asia, as two studies
from Taiwan and Hong Kong showed that levoﬂoxacin-
based triple therapies were at most comparable to quadruple
therapy [95, 102].
As previously mentioned, the quadruple regimen re-
quires the administration of a complex scheme [20]. On the
contrary, levoﬂoxacin-based regimens (with amoxicillin and
PPIs administered twice daily, and levoﬂoxacin every 12 or
24 hours) represent an encouraging alternative to quadruple
therapy, with the advantage of simplicity. Furthermore,
the quadruple regimen is associated with a relatively high
incidence of adverse eﬀects [20]. In contrast, levoﬂoxacinGastroenterology Research and Practice 5
Study
or subcategory
Levoﬂoxacin Quadruple OR (random)  Weight OR  (random)  
95% CI  % 95%  CI
Bilardi et al. 2004   31/44              17/46         10.87 4.07 [1.68, 9.83]        
Gisbert et al. 2005   21/31              24/36         10.17 1.05 [0.38, 2.92]        
Nista et al. 2003a    66/70              44/70         9.69 9.75 [3.18, 29.87]       
Nista et al. 2003b    63/70              44/70         10.69 5.32 [2.12, 13.33]       
Nista et al. 2004a    26/30              25/35         8.9 2.6 [0.72, 9.38]        
Nista et al. 2004b    24/30              25/35         9.51 1.6 [0.50, 5.09]        
Nista et al. 2005     37/50              34/50         10.94 1.34 [0.56, 3.19]        
Orsi et al. 2003      43/50              44/50         9.45 0.84 [0.26, 2.7]        
Perri et al. 2003     38/60              50/60         10.98 0.35 [0.15, 0.81]        
Wong et al. 2002      51/56              48/53         8.81 1.06 [0.29, 3.9]        
Total (95% CI)   491                505 100 1.8 [0.94, 3.46]
Total events: 400 (levoﬂoxacin); 355 (quadruple)
0.1 0.2  0.5  1 2  5  10
 Favours quadruple    Favours  levoﬂoxacin
n/N n/N
Test for heterogeneity: χ2 = 35.78; df = 9( P<0.0001); I2 = 74.8%
Test for overall eﬀect: Z = 1.77 (P = 0.08)
Figure 1: Meta-analysis comparing H. pylori eradication eﬃcacy with levoﬂoxacin-based triple regimens versus quadruple therapy, as
second-line “rescue” regimen after failure of a proton pump inhibitor-amoxicillin-clarithromycin.
is generally well tolerated, and most adverse events asso-
ciated with its use are mild to moderate in severity and
transient [68]. The most frequent adverse eﬀects aﬀect the
gastrointestinal tract [68]. Occasional cases of tendinitis and
tendon rupture have been reported in the literature with
levoﬂoxacin therapy [51, 68]. However, data derived from
more than 15 million prescriptions in the US indicated
the rate is fewer than 4 per million prescriptions [107].
Clostridium diﬃcile infection may be associated with the
use of this broad spectrum activity antibiotic [68]. In
the aforementioned systematic review [70], adverse eﬀects
were reported, overall, by 18% of the patients treated with
levoﬂoxacin-based therapies, and these adverse eﬀects were
severe (deﬁned so by the authors or explaining treatment
discontinuation) in only 3% of the cases. Furthermore,
the incidence of adverse eﬀects was not diﬀerent when
levoﬂoxacin-amoxicillin-PPI was administered for 7 or 10
days, supporting the aforementioned recommendation of
prescribing the more eﬀective 10-day regimen. Moreover,
two meta-analyses have demonstrated a lower incidence
of adverse eﬀects with levoﬂoxacin-based treatments than
with the quadruple combinations [69, 70]. Finally, it has
recently been demonstrated that moxiﬂoxacin-containing
triple regimen is more eﬀective and better tolerated than
the bismuth-containing quadruple therapy in the second-
line treatment of H. pylori infection [106].
Unfortunately, it has been shown that resistance to
quinolones is easily acquired, and in countries with a high
consumption of these drugs, the resistance rate is increasing
and is already relatively high [75, 88, 95, 108–125]. More
importantly, it has been demonstrated that the presence of
levoﬂoxacin resistance signiﬁcantly reduce the eradication
rate following a therapy with this antibiotic [75, 88, 118, 126,
127]. Therefore, it has been suggested to reserve levoﬂoxacin
for “rescue” treatment to avoid the increase of the resistance
phenomenon [128].
3.2. “Rescue” Regimen after PPI-Amoxicillin-Nitroimidazole
Failure. After PPI-amoxicillin-nitroimidazole failure, re-
treatmentwithPPI-amoxicillin-clarithromycinhasprovedto
be very eﬀective, and it seems to be a logical strategy, as while
amoxicillinismaintained(whichdoesnotinduceresistance),
clarithromycin is substituted for metronidazole. Further-
more, the absence of cross-resistance among nitroimidazoles
and clarithromycin favors this position. With this therapy,
some authors [46]h a v ea c h i e v e dH. pylori eradication in
85% of cases, while others have reported success rates of
86% [129] or even 100%% [130]. In favor of this strategy
is the study by Magaret et al. [131] who studied a group
of 48 patients after failure of previous H. pylori therapy
with a metronidazole-containing regimen and randomized
them to either lansoprazole, amoxicillin, and clarithromycin
twice daily for 14 days (i.e., the logical approach with triple
therapy not repeating metronidazole) or to lansoprazole,
bismuth, metronidazole and tetracycline for 14 days (i.e.,
the quadruple therapy repeating metronidazole). Intention-
to-treat eﬃcacies were 75% for triple regimen and 71% for
quadruple. Although this diﬀerence did not reach statistical
signiﬁcance, the small sample size of this study does not
preclude the possibility of a small but clinically signiﬁcant
diﬀerence in eﬃcacy between the regimens.
3.3. “Rescue” Regimen after PPI-Clarithromycin-Nitroim-
idazole Failure. As previously mentioned, acquired bacte-
rial resistance to metronidazole or clarithromycin results
primarily from the previous treatment failure [132], and
therefore the ﬁrst choice probably should not be a regimen
that combines these two antibiotics in the same regimen [30,
31, 133]. Although this regimen is very eﬀective [8], patients
who are not cured will probably have double resistance
[134, 135], and no logical empirical treatment remains
afterwards (although, more recently, the levoﬂoxacin-based
regimens may represent an option). Thus, some authors
have demonstrated that initial regimens containing both
clarithromycin and nitroimidazole are associated with sig-
niﬁcantly worse results overall, with lower eradication rates
after logically chosen second-line therapy and sensitivity-
directed third-line therapy; these poor results were due to
the emergence of multiply resistant strains as evidenced by
the results of culture testing after the second failed course6 Gastroenterology Research and Practice
[136]. In summary, due to problems with resistance it could
be suggested that both key antibiotics—clarithromycin and
metronidazole—should not be used together until a valid
empirical back up regimen is available [30].
Nevertheless, if culture is not performed after failure
of PPI-clarithromycin-metronidazole, and hence antibiotic
susceptibility is unknown, several “rescue” options may be
suggested. Firstly, omeprazole plus amoxicillin, with a high
dose of both the antibiotic and the antisecretor, could,
in theory, be recommended [133, 137]; however, we must
remember that this “old-fashioned” dual combination has
achieved disappointing results in many countries [138].
Therefore, a second antibiotic should be added, and at this
point a diﬃcult decision appears, as both antibiotics used in
the ﬁrst trial (clarithromycin and metronidazole) are capable
of inducing secondary resistance to H. pylori, playing a
negative role in future eﬃcacy [134, 139–144]. Nevertheless,
the following possibilities exist.
3.3.1. Readministering Metronidazole. Due to the fact that
metronidazole resistance is frequent and clinically relevant
[134, 139–141], if this antibiotic is readministered, it should
be used within bismuth-based quadruple regimen (thus PPI
might reduce the negative eﬀect of metronidazole resistance
[57, 141, 145]). With this regimen, eradication rates up to
80% have been achieved [46].
3.3.2. Readministering Clarithromycin. Several studies have
underlined the relevance of clarithromycin resistance [134,
139, 140, 142], which advise against readministering this
antibiotic. Therefore, a further option which has been
proposedistoadd(e.g.,toPPI-amoxicillin-clarithromycin)a
fourth medication (as bismuth [146, 147]) with bactericidal
eﬀect against H. pylori, with which 70% eradication rate has
been achieved [46].
3.3.3. Readministering No Antibiotic. A ﬁnal alternative,
obviously, consists of no readministering either metronida-
zole or clarithromycin. Although only published in abstract
form, one study has prescribed ranitidine bismuth citrate,
tetracycline, and amoxicillin for 2 weeks and has reported
the eradication in 89% of the cases who had previously failed
PPI,clarithromycin,andtinidazole[148].Theseencouraging
results may be due, at least in part, to the use of ranitidine
bismuth citrate instead of bismuth in this regimen, as “clas-
sic”tripletherapywithbismuth,tetracycline,andamoxicillin
has been previously considered relatively ineﬀective. Finally,
although not speciﬁcally evaluated in PPI-clarithromycin-
metronidazole failures, rifabutin, or levoﬂoxacin-based reg-
imens (e.g., PPI, amoxicillin and either levoﬂoxacin or
rifabutin) could play a role in this diﬃcult situation. How-
ever, several concerns remain regarding rifabutin treatment
[149]. Firstly, this drug is very expensive. Secondly, severe
leucopoenia and thrombocytopenia have been reported in
some patients treated with rifabutin. Finally, there is some
concern about a wide-spread use of rifabutin, a member of
a class of established antimycobacterial drugs, in patients
with H. pylori infection. Because multiresistant strains of
Mycobacterium tuberculosis increase in numbers, indications
for these drugs should be chosen very carefully to avoid
further acceleration of development of resistance.
3.4. “Rescue” Regimen after Nonbismuth Quadruple “Sequen-
tial” and “Concomitant” Treatment Failure. As previously
mentioned, the most widely recommended treatment for
the eradication of H. pylori is the standard, or PPI-based
triple therapy, which combines 2 antibiotics (clarithromycin
plus amoxicillin or metronidazole). However, one recent
innovation, postulated as an alternative to standard triple
therapy,issequentialtreatment,whichinvolvesasimpledual
regimen including a PPI plus amoxicillin for the ﬁrst 5 days
followed by a triple regimen including a PPI, clarithromycin,
and tinidazole for the following 5 days [2]. On the other
hand, the concept of a nonbismuth quadruple regimen or
“concomitant” regimen has recently resurfaced. Traditional
standard triple therapy (PPI-clarithromycin-amoxicillin)
can easily be converted to “concomitant” therapy by the
additionof500mgofmetronidazoleortinidazoletwicedaily
[3].
Itremainsunclearhowfailureofnon-bismuthquadruple
“sequential” or “concomitant” therapy should be man-
aged. One potential disadvantage of these therapies is that
patients with failed eradication would have limited options
for further treatment, because they would already have
received 3 diﬀerent antibiotics: amoxicillin, clarithromycin,
and nitroimidazole. However, the recent appearance of
levoﬂoxacin may overcome this problem. Thus, Zullo et
al. [150] recently performed a pilot study on patients who
failed sequential therapy; following 10-day triple therapy
with a PPI, levoﬂoxacin, and amoxicillin, H. pylori infection
was successfully cured in 86% of cases. In another study,
Perna et al. [118] prescribed a 10-day triple regimen with a
PPI, levoﬂoxacin, and amoxicillin in patients in whom ﬁrst
treatment with either standard 10-day triple or sequential
therapy(only10patients)hadfailed.H.pyloriwaseradicated
in73%ofcases,althoughtheauthorsdonotprovideseparate
eﬃcacy rates depending on the ﬁrst (failure) treatment.
These data seem to indicate that a triple regimen (PPI-
levoﬂoxacin-amoxicillin) is a suitable approach for second-
line treatment in patients whose sequential—and probably
also concomitant—therapy fails.
4. Conclusion
Even with the current most eﬀective treatment regimens,
≥20% of patients will fail to eradicate H. pylori infection.
This paper seems important at the present time, as therapy
forH.pyloriinfectionisbecomingmoreandmorefrequently
prescribed. Nowadays, apart from having to know well ﬁrst-
line eradication regimens, we must also be prepared to
face treatment failures. Therefore, in designing a treatment
strategy we should not only focus on the results of primary
therapy alone, but also on the ﬁnal—overall—eradication
rate.
The choice of a “rescue” treatment depends on which
treatment is used initially. If a ﬁrst-line clarithromycin-
based regimen was used, a second-line metronidazole-basedGastroenterology Research and Practice 7
treatment(suchasthequadrupletherapy)maybeusedafter-
wards, and then a levoﬂoxacin-based combination would
be a third-line “rescue” option. Alternatively, it has recently
beensuggestedthatlevoﬂoxacin-based“rescue”therapycon-
stitutes an encouraging 2nd-line strategy, representing an
alternative to quadruple therapy in patients with previous
PPI-clarithromycin-amoxicillin failure, with the advantage
of eﬃcacy, simplicity, and safety. In this case, quadruple
regimen may be reserved as a 3rd-line “rescue” option.
Even after two consecutive failures, several studies have
demonstrated that H. pylori eradication can ﬁnally be
achieved in almost all patients if several “rescue” therapies
are consecutively given [22, 151]. As a ﬁnal conclusion,
therefore,theattitudeinH.pylorieradicationtherapyfailure,
even after two or more unsuccessful attempts, should be to
ﬁght and not to surrender [152].
Abbreviations
H. pylori: Helicobacter pylori
PPI: Proton pump inhibitor.
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